Kite Pharma, a subsidiary of Gilead Sciences, has made public plans to push back by roughly one year the planned achievement of commercial production at its site in Urbana. Alert readers will recall that the company is constructing a new 279,000-square-foot plant in Urbana, Maryland after purchasing the 20 acre property on Bennett Creek Blvd in November 2018 for $7.5 million. The project delay is being attributed to building enhancements. It is understood that the new site will manufacture Kite’s producers of chimeric antigen receptor T (CAR T) therapies, including Yescarta, which is Kite Pharma’s commercially available CAR T therapy. Learn More